121 related articles for article (PubMed ID: 6404660)
1. Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):661-7. PubMed ID: 6404660
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women.
Lemay A; Faure N; Labrie F
Fertil Steril; 1982 Feb; 37(2):193-200. PubMed ID: 6800846
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.
Lemay A; Metha AE; Tolis G; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1983 May; 39(5):668-73. PubMed ID: 6404661
[TBL] [Abstract][Full Text] [Related]
5. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
Lemay A; Labrie F; Raynaud JP
Int J Fertil; 1980; 25(3):203-12. PubMed ID: 6108931
[TBL] [Abstract][Full Text] [Related]
6. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
Baumann R; Kuhl H; Taubert HD; Sandow J
Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
[TBL] [Abstract][Full Text] [Related]
7. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
Faure N; Labrie F; Belanger A; Lemay A; Raynaud JP; Von der Ohe M; Fazekas AT
J Endocrinol Invest; 1982; 5(6):355-60. PubMed ID: 6820372
[TBL] [Abstract][Full Text] [Related]
9. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
Grimes EM; Thompson IE; Taymor ML
Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
[TBL] [Abstract][Full Text] [Related]
10. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
11. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
Fraser HM; Nestor JJ; Vickery BH
Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
[TBL] [Abstract][Full Text] [Related]
12. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
Skarin G; Nillius SJ; Wide L
Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
[TBL] [Abstract][Full Text] [Related]
13. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
[TBL] [Abstract][Full Text] [Related]
14. Interference in follicular maturation following acute intranasal LH-RH agonist administration during mid and late follicular phase.
Lemay A; Faure N
Int J Fertil; 1988; 33(1):60-7. PubMed ID: 2896176
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of action of a new low-dosed combined oral contraceptive.
Dericks-Tan JS; Schneider K; Taubert HD
Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the postcoital contraceptive effect of LH-RH in the rat. I. Serum hormone levels during chronic LH-RH Administration.
Beattie CW; Corbin A; Cole G; Corry S; Jones RC; Koch K; Tracy J
Biol Reprod; 1977 Apr; 16(3):322-32. PubMed ID: 321040
[TBL] [Abstract][Full Text] [Related]
17. Luteolytic effect of intranasal administration of [D-Ser(TBU)6,DES-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in normal women.
Lemay A; Labrie F; Belanger A; Raynaud JP
Fertil Steril; 1979 Dec; 32(6):646-51. PubMed ID: 389676
[TBL] [Abstract][Full Text] [Related]
18. Effect of postovulatory treatment with a luteinizing hormone-releasing hormone analog on the plasma level of progesterone in women.
Koyama T; Ohkura T; Kumasaka T; Saito M
Fertil Steril; 1978 Nov; 30(5):549-52. PubMed ID: 363461
[TBL] [Abstract][Full Text] [Related]
19. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
20. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
Sheehan KL; Casper RF; Yen SS
Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
